The ends justify the mean: Outcome measures for estimating the value of new cancer therapies

Health Outcomes Research in Medicine

Volumn 3, Issue 1, 2012, Pages

  Davies, Andrew ^a   Briggs, Andrew ^a   Schneider, John ^a   Levy, Adrian ^a   Ebeid, Omar ^a   Wagner, Samuel ^b   Kotapati, Srividya ^b   Ramsey, Scott ^c  

^a ICON PLC   (United Kingdom)

^b BRISTOL MYERS SQUIBB   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Modeling; Oncology; Overall survival; Survival analysis

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IPILIMUMAB; IRINOTECAN; MELANOCYTE PROTEIN PMEL 17;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER THERAPY; COLORECTAL CANCER; FOLLOW UP; HUMAN; LIFE EXPECTANCY; MELANOMA; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REIMBURSEMENT;

EID: 84862238782     PISSN: None     EISSN: 18771319     Source Type: Journal    
DOI: 10.1016/j.ehrm.2012.01.001     Document Type: Article

References (41)

1. Di Maio M, Gallo C, De Maio E, et al. Methodological aspects of lung cancer clinical trials in the era of targeted agents. Lung Cancer. 2009; 67(2):127-135.
2. Hoos A, Eggermont AM, Janetzki S, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst. 2010;102(18):1388-1397.
3. Huang L, Cronin KA, Johnson KA, Mariotto AB, Feuer EJ. Improved survival time: what can survival cure models tell us about populationbased survival improvements in late-stage colorectal, ovarian, and testicular cancer? Cancer. 2008;112(10):2289-2300. (Pubitemid 351628641)
4. Ludbrook J, Royse AG. Analysing clinical studies: principles, practice and pitfalls of Kaplan-Meier plots. ANZ J Surg. 2008;78(3):204-210. (Pubitemid 351207401)
5. Ramsey SA, Schickedanz A. How should we define value in cancer care? Oncologist. 2010;15(Suppl 1):1-4.
6. Seppä K, Hakulinen T, Kim HJ, Läärä E. Cure fraction model with random effects for regional variation in cancer survival. Stat Med. 2010;29(27): 2781-2793.
7. Tappenden P, Chilcott J, Ward S, Eggington S, Hind D, Hummel S. Methodological issues in the economic analysis of cancer treatments. Eur J Cancer. 2006;42(17):2867-2875. (Pubitemid 44667482)
8. Ahmed FE, Vos PW, Holbert D. Modeling survival in colon cancer: a methodological review. Mol Cancer. 2007;6:15.
9. Fleming TR, Lin DY. Survival analysis in clinical trials: past developments and future directions. Biometrics. 2000;56(4):971-983.
10. Gu Y, Sinha D, Banerjee S. Analysis of cure rate survival data under proportional odds model. Lifetime Data Anal. 2011;17(1):123-134.
11. Kim S, Chen MH, Dey DK. A new threshold regression model for survival data with a cure fraction. Lifetime Data Anal. 2011;17(1):101-122.
12. Peng Y, Taylor JMG, Yu B. A marginal regression model for multivariate failure time data with a surviving fraction. Lifetime Data Anal. 2007; 13(3):351-369.
13. Zhang J, Peng Y. Accelerated hazards mixture cure model. Lifetime Data Anal. 2009;15(4):455-467.
14. Fisher LD, Lin DY. Time-dependent covariates in the Cox proportionalhazards regression model. Annu Rev Public Health. 1999;20:145-157. (Pubitemid 29242575)
15. U.S. Department of Health and Human Services Food and Drug Administration. Guidance for Industry Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. Rockville MD: U.S. Food and Drug Administration; 2007.
16. McCain JA. The ongoing evolution of endpoints in oncology. Manag Care. 2010;19(5)(Suppl 1):1-12.
17. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. Oxford, UK: Oxford University Press; 2005.
18. Collet D. Modelling Survival Data in Medical Research. 2nd ed. London: Chapman & Hall; 2003.
19. Guyot P, Welton NJ, Ouwens JN, Ades AE. Survival time outcomes in randomized, controlled trials and meta-analyses: the parallel universes of efficacy and cost-effectiveness. Value Health. 2011;14:640-646.
20. Huang X, Chen S, Soong SJ. Piecewise exponential survival trees with time-dependent covariates. Biometrics. 1998;54(4):1420-1433. (Pubitemid 29018625)
21. Lee J, Kim J, Jung SH. Bayesian analysis of paired survival data using a bivariate exponential distribution. Lifetime Data Anal. 2007;13(1): 119-137.
22. Wellner JA. On an exponential bound for the Kaplan-Meier estimator. Lifetime Data Anal. 2007;13(4):481-496.
23. Zisman A, Pantuck AJ, Dorey F, et al. Mathematical model to predict individual survival for patients with renal cell carcinoma. J Clin Oncol. 2002; 20(5):1368-1374. (Pubitemid 34177444)
24. Jenkins S. Survival analysis (2005). Available at: http://www.iser.essex. ac. uk/files/teaching/stephenj/ec968/pdfs/ec968lnotesv6.pdf. Accessed January 24, 2012.
25. National Institute for Health and Clinical Excellence. Colorectal cancer - capecitabine and tegafur uracil (TA61). (Capecitabine and tegafur uracil for metastatic colorectal cancer). Available at: http://www.nice.org.uk/TA061. Accessed January 24, 2012.
26. National Institute for Health and Clinical Excellence. Breast cancer - capecitabine (TA62). (Guidance on the use of capecitabine for the treatment of locally advanced or metastatic breast cancer). Available at: http://www.nice.org.uk/TA062. Accessed January 24, 2012.
27. National Institute for Health and Clinical Excellence. Colorectal cancer (advanced) - irinotecan, oxaliplatin and raltitrexed (TA93). (Irinotecan, oxaliplatin and raltitrexed for advanced colorectal cancer). Available at: http://www.nice.org.uk/TA093. Accessed January 24, 2012.
28. National Institute for Health and Clinical Excellence. Breast cancer - gemcitabine (TA116). (Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer). Available at: http://www.nice.org.uk/TA116. Accessed January 24, 2012.
29. National Institute for Health and Clinical Excellence. Colorectal cancer (metastatic) - bevacizumab and cetuximab (TA118). (Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer). Available at: http://www.nice.org.uk/TA118. Accessed January 24, 2012.
30. National Institute forHealth andClinical Excellence. Lung cancer (non-smallcell) - pemetrexed (TA124). (Pemetrexed for the treatment of non-small-cell lung cancer). Available at: http://www.nice.org.uk/TA124. Accessed January 24, 2012.
31. National Institute for Health and Clinical Excellence. Mesothelioma - pemetrexed disodium (TA135). (Pemetrexed disodium for the treatment of mesothelioma). Available at: http://www.nice.org.uk/TA135. Accessed January 24, 2012.
32. National Institute for Health and Clinical Excellence. Lung cancer (nonsmall- cell) - erlotinib (TA162). (Erlotinib for the treatment of non-small cell lung cancer). Available at: http://www.nice.org.uk/TA162. Accessed January 24, 2012.
33. National Institute for Health and Clinical Excellence. Lung cancer (smallcell) - topotecan (TA184). (Topotecan for the treatment of relapsed smallcell lung cancer). Available at: http://www.nice.org.uk/TA184. Accessed January 24, 2012.
34. National Institute for Health and Clinical Excellence. Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line) (TA189). (Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line). Available at: http://www.nice.org.uk/TA189. Accessed January 24, 2012.
35. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335-2342. (Pubitemid 38702844)
36. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8): 711-723.
37. Morden JP, Lambert PC, Latimer N, Abrams KR, Wailoo AJ. Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study. BMC Med Res Methodol. 2011;11:4.
38. Branson M, Whitehead J. Estimating a treatment effect in survival studies in which patients switch treatment. Stat Med. 2002;21(17): 2449-2463. (Pubitemid 34960010)
39. Robins JM, Tsiatis AA. Correcting for non-compliance in randomized trials using rank preserving structural failure time models. Commun Stat Theory Methods. 1991;20(8):2609-2631.
40. Royston P, Parmar MK. Flexible proportional-hazards and proportionalodds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med. 2002;21(15): 2175-2197. (Pubitemid 34830755)
41. Jackson C, Sharples L, Thompson S. Survival models in health economic evaluations: balancing fit and parsimony to improve prediction. Int J Biostat. 2010;6(1). Article 34.